~~<i id='18764C729D'><strike id='18764C729D'><tt id='18764C729D'><pre id='18764C729D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：Wikipedia 2025-10-02 10:48:28 - browse：64

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Stem cell clinics for heart failure: buyer be wary

knowledge

leisure time

focus

knowledge

HyacinthEmpinado/STATInPhoenix,wheredaytimetemperaturesaretopping110degreesFahrenheitforthethirdstra

WSS

The drug industry sees a key ally in the Senate prevail

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Biden calls for immediate release of Niger's president amid apparent coup

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Pumping milk in bathrooms at health conferences is common

Gilgo Beach: Police identify another victim in serial killing investigation

explore

entertainment

knowledge

New air purifier tech could be key to improving indoor air quality

Dana Farber says 6 studies to be retracted and 31 corrected

Trump demands the U.S. pay no more for drugs than other countries … again

Cardiologists urge adding sexual orientation, gender identity to health records

23andMe had bad news about my health. I wish a person had delivered it

Dana Farber says 6 studies to be retracted and 31 corrected

United colonoscopy coverage change 'may cost lives,' doctors say

A pediatrician calls for Congress to pass the child tax credit deal

DIEP, the 'gold standard' of breast reconstruction, is under threat

High breast density mammograms need follow

leisure time

Gilgo Beach: Police identify another victim in serial killing investigation

Medicare drug price lawsuits could be good politics for Biden

The drug industry sees a key ally in the Senate prevail

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Prior authorization reform is both possible and imperative

Inaction leaves children at risk from dangerous chemotherapy drug

focus

focus

focus

knowledge